Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7.
Furlan
Ingrid
I
Batz
Christiane
C
Flotho
Christian
C
Mohr
Brigitte
B
Lübbert
Michael
M
Suttorp
Meinolf
M
Niemeyer
Charlotte M
CM
D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use*; D001374:Azacitidine / Q000494:pharmacology / Q000627:therapeutic use*; D001854:Bone Marrow Cells / Q000648:ultrastructure; D002116:Calcitonin / Q000235:genetics; D002897:Chromosomes, Human, Pair 7; D002999:Clone Cells / Q000648:ultrastructure; D003131:Combined Modality Therapy; D018899:CpG Islands; D019175:DNA Methylation / Q000187:drug effects; D011905:Genes, ras; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D054429:Leukemia, Myelomonocytic, Juvenile / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D008297:Male; D009006:Monosomy; D009363:Neoplasm Proteins / Q000235:genetics; D017354:Point Mutation; D011401:Promoter Regions, Genetic; D011498:Protein Precursors / Q000235:genetics; D012074:Remission Induction
D000964:Antimetabolites, Antineoplastic; D009363:Neoplasm Proteins; D011498:Protein Precursors; D002116:Calcitonin; D001374:Azacitidine